Vaccine (mRNA vaccine) · Immune activation, directed at SARS-CoV-2 spike protein · developed by ImmunityBio
AAHI-SC2 is a self-amplifying RNA vaccine encoding the SARS-CoV-2 spike protein, delivered via nanostructured lipid carrier. It is studied for COVID-19 prevention.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05370040 | Phase 1/2 | COVID-19 | Terminated | IBRX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
COVID-19
Updated Oct 3, 2026. Something wrong or missing? Report it on the IBRX page.
See IBRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IBRX catalysts and pipeline →